Abstract:Background and Objective Nevus of Ota is a benign dermal and mucosal melanocytic nevus that can be cured by Q-switched lasers. However, the incidence rate of post-treatment hyperpigmentation in Asian patients remains high. Low-fluence Q-switched Nd:YAG laser (QSNY) has been proved effective in the early treatment of nevus of Ota. Q-switched alexandrite laser (QSAL) was found to achieve a higher success rate and lower complication rate than QSNY. This study aims to evaluate the efficacy and safety of low-fluence 755 nm QSAL in the treatment of nevus of Ota. Materials and Methods A total of 81 patients with nevus of Ota were retrospectively evaluated. Among them, 39 went through the high-fluence QSAL (3 mm spot, 5.0-8.0 J/cm(2)) and 42 were treated by low-fluence QSAL (5 mm spot, 2.2-2.8 J/cm(2)). Treatments were given every 6 months three times. Standard photos of the lesions were taken to evaluate the efficacy. All adverse events were noted. Results The low-fluence QSAL group achieved a significantly higher mean efficacy score than the high-fluence QSAL group after the first treatment (3.62 +/- 0.85 vs. 2.9 +/- 0.79, P < 0.001) and at the final follow-up visit (4.52 +/- 0.63 vs. 4.03 +/- 0.96, P < 0.05). Post-inflammation hyperpigmentation rate was significantly lower in the low-fluence QSAL group than in the high-fluence QSAL group (4.8% vs. 25.6%, P < 0.001). No patient reported hyperkeratosis, scarring, bleeding, skin textural change, or recurrence at the final visit in either group. Conclusion The low-fluence QSAL is more effective and safer than the traditional high-fluence QSAL because of its better clinical outcome and lower complication rate in the treatment of nevus of Ota. Lasers Surg. Med. (c) 2021 Wiley Periodicals LLC.

Analysis of 28 Chinese Cases of Bilateral Nevus of Ota and Therapeutic Results With the Q-Switched Alexandrite Laser

A Retrospective Analysis of the Clinical Efficacies and Recurrence of Q-switched Nd:YAG Laser Treatment of Nevus of Ota in 224 Chinese Patients

A Retrospective Study on the Characteristics of Treating Nevus of Ota by 1064-Nm Q-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser

A Study on the Clinical Characteristics of Treating Nevus of Ota by Q-switched Nd:YAG Laser.

Analysis of Nevus of Ota Treated by Q-switched Nd:YAG Laser(Reported of 248 Cases)

A retrospective study of q-switched alexandrite laser in treating nevus of ota.

Successful and Quick Treatment of Nevus of Ota with 755nm Picosecond Laser in Chinese

Beneficial Effects of Treatment with Low‐Fluence 755‐nm Q‐Switched Alexandrite Laser for Nevus of Ota

Q-switch Nd: YAG laser in treatment of three cases of bilateral naevus of Ota

Efficacy and safety of 755 nm Q-switched alexandrite laser in the treatment of 114 cases of acquired bilateral nevus of Ota-like macules

Picosecond alexandrite laser treatment of nevus of Ota in children

Efficacy and Safety of Q-switched Lasers for the Treatment of Naevus of Ota in Children: a Retrospective Analysis

Q-switched ruby laser therapy for acquired bilateral naevus of Ota-like macules in Chinese

Nevus of Ota: Combination Treatment with Q-Switched neodymium-doped yttrium aluminum garnet laser and fractional CO2 laser

Clinical Analysis of 1 168 Patients of Nevus of Ota

Aesthetic Removal Of Large Melanocytic Nevi Using Co2 Lasers With A Programmed 4-Step Approach

A Split-Face, Single-Blinded, Randomized Controlled Comparison of Alexandrite 755-Nm Picosecond Laser Versus Alexandrite 755-Nm Nanosecond Laser in the Treatment of Acquired Bilateral Nevus of Ota–like Macules

Analysis of Therapeutic Effect of Versa Pulse C with HELP G in Treatment of Nevus of Ota:Report of 298 Cases

Low-Fluence Q-Switched Nd: YAG Laser (LF-QSNY) May Be a Better Choice for the Treatment of Early Nevus of Ota: A Prospective Self-Controlled Trial of LFQS and Picosecond Alexandrite Laser

Comparison of the efficacy and safety of a 730‐nm picosecond titanium sapphire laser and a 1064‐nm picosecond neodymium yttrium aluminum garnet laser for the treatment of acquired bilateral nevus of Ota‐like macules: A split‐face, evaluator‐blinded, randomized, and controlled pilot trial